Corpus overview


MeSH Disease

Human Phenotype

Hypertension (64)

Fever (16)

Obesity (16)

Cough (14)

Dyspnea (10)


    displaying 51 - 60 records in total 64
    records per page

    When Chronic Diseases Meet Infectious Diseases MESHD: A Proposal Toward Healthy Aging: Lessons from COVID-19 Outbreak

    Authors: Juan Carlos Gómez-Verjan; Carmen García-Peña; Nadia A. Rivero-Segura

    id:202005.0035/v1 Date: 2020-05-03 Source:

    As the novel COVID-19 disease spreads TRANS around the world, the most affected population are those who suffer from the most common chronic diseases, such as obesity HP obesity MESHD, hypertension HP hypertension MESHD, and type 2 diabetes MESHD, which are quite associated with the so-called age TRANS-related diseases. On the other hand, since the Spanish influenza outbreak, humanity has not experienced an infectious disease MESHD that synergizes so quickly with chronic diseases MESHD, making it mortal for those individuals with comorbidities. In this context, COVID-19 is challenging for health systems all around the world due to the high prevalence SERO of chronic diseases MESHD. Nowadays, we are facing the beginning of a new era in which health infectious and chronic diseases meet. Therefore, epidemiologic and biomedical researchers must work together to solve further contingencies, and politicians should direct science-centered decisions on public health. In the present paper, we make an urgent call to learn from the COVID-19 lessons in order to mitigate the chronic diseases prevalence SERO and to address the influence of the infectious diseases on the aging process; since we are about to begin the Decade of Healthy Aging.

    COVID-19 Infections and Outcomes in a Live Registry of Heart Failure MESHD Patients Across an Integrated Health Care System

    Authors: Cesar Caraballo; Megan McCullough; Michael Fuery; Fouad Chouairi; Craig Keating; Neal Ravindra; Elliott Miller; Maricar Malinis; Nitu Kashyap; Allen Hsiao; Francis Perry Wilson; Jeptha Curtis; Matthew Grant; Eric J Velazquez; Nihar Desai; Tariq Ahmad

    doi:10.1101/2020.04.27.20082016 Date: 2020-05-03 Source: medRxiv

    Background: Patients with comorbid conditions have a higher risk of mortality with SARS-CoV-2 (COVID-19) infection, but the impact on heart failure MESHD patients living near a disease hotspot is unknown. Therefore, we sought to characterize the prevalence SERO and outcomes of COVID-19 in a live registry of heart failure MESHD patients across an integrated health care system in Connecticut. Methods: In this retrospective analysis, the Yale Heart Failure Registry (NCT04237701) that includes 26,703 patients with heart failure MESHD across a 6-hospital integrated health care system in Connecticut, was queried on April 16th, 2020 for all patients tested for COVID-19. Sociodemographic and geospatial data as well as, clinical management, respiratory failure HP respiratory failure MESHD, and patient mortality were obtained via the real-time registry. Data on COVID-19 specific care was extracted by retrospective chart review. Results: COVID-19 testing was performed on 900 symptomatic patients, comprising 3.4% of the Yale Heart Failure Registry (N=26,703). Overall, 206 (23%) were COVID-19+. As compared to COVID-19-, these patients were more likely to be older, black, have hypertension HP hypertension MESHD, coronary artery disease MESHD, and were less likely to be on renin angiotensin blockers (P<0.05, all). COVID-19- patients tended to be more diffusely spread across the state whereas COVID-19+ were largely clustered around urban centers. 20% of COVID-19+ patients died, and age TRANS was associated with increased risk of death [OR 1.92 95% CI (1.33-2.78); P<0.001]. Among COVID-19+ patients who were [≥]85 years of age TRANS rates of hospitalization were 87%, rates of death 36%, and continuing hospitalization 62% at time of manuscript preparation. Conclusions: In this real-world snapshot of COVID-19 infection MESHD among a large cohort of heart failure MESHD patients, we found that a small proportion had undergone testing. Patients found to be COVID-19+ tended to be black with multiple comorbidities and clustered around lower socioeconomic status communities. Elderly TRANS COVID-19+ patients were very likely to be admitted to the hospital and experience high rates of mortality.

    Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study

    Authors: Shiqiang Xiong; Lin Liu; Feng Lin; Jinhu Shi; Lei Han; Huijian Liu; Lewei He; Qijun Jiang; Zeyang Wang; Wenbo Fu; Zhigang Li; Qing Lu; Zhinan Chen; Shifang Ding

    doi:10.21203/ Date: 2020-05-01 Source: ResearchSquare

    Background A cluster of acute respiratory illness MESHD, now known as Corona Virus Disease MESHD 2019 (COVID-19) caused by 2019 novel coronavirus (SARS-CoV-2), has become a global pandemic. Aged TRANS population with cardiovascular diseases MESHD are more likely be to infected with SARS-CoV-2 and result in more severe outcomes and elevated case-fatality rate. Meanwhile, cardiovascular diseases MESHD have a high prevalence SERO in the middle- aged TRANS and elderly TRANS population. However, despite of several researches in COVID-19, cardiovascular implications related to it still remains largely unclear. Therefore, a specific analysis in regard to cardiovascular implications of COVID-19 patients is in great need.Methods In this single-centered, retrospective, observational study, 116 patients with laboratory-confirmed COVID-19 were enrolled, who admitted to the General Hospital of Central Theater Command (Wuhan, China) from January 20 to March 8, 2020. The demographic data, underlying comorbidities, clinical symptoms and signs, laboratory findings, chest computed tomography, treatment measures, and outcome data were collected from electronic medical records. Data were compared between non-severe and severe cases. Results Of 116 hospitalized patients with COVID-19, the median age TRANS was 58.5 years (IQR, 47.0-69.0), and 36 (31.0%) were female TRANS. Hypertension HP Hypertension MESHD (45 [38.8%]), diabetes MESHD (19 [16.4%]), and coronary heart disease MESHD (17 [14.7%]) were the most common coexisting conditions. Common symptoms included fever HP fever MESHD [99 (85.3%)], dry cough MESHD cough HP (61 [52.6%]), fatigue HP fatigue MESHD (60 [51.7%]), dyspnea HP dyspnea MESHD (52 [44.8%]), anorexia HP anorexia MESHD (50 [43.1%]), and chest discomfort (50 [43.1%]). Local and/or bilateral patchy shadowing were the typical radiological findings on chest computed tomography. Lymphopenia HP Lymphopenia MESHD (lymphocyte count, 1.0 × 109/L [IQR, 0.7-1.3]) was observed in 66 patients (56.9%), and elevated lactate dehydrogenase (245.5 U/L [IQR, 194.3-319.8]) in 69 patients (59.5%). Hypokalemia HP Hypokalemia MESHD occurred in 24 (20.7%) patients. Compared with non-severe cases, severe cases were older (64.0 years [IQR, 53.0-76.0] vs 56.0 years [IQR, 37.0-64.0]), more likely to have comorbidities (35 [63.6%] vs 24 [39.3%]), and more likely to develop acute cardiac injury MESHD (19 [34.5%] vs 4 [6.6%]), acute heart failure MESHD (18 [32.7%] vs 3 [4.9%]), and ARDS (20 [36.4%] vs 0 [0%]). During hospitalization, the prevalence SERO of new onset hypertension HP hypertension MESHD was significantly higher in severe patients (55.2% vs 19.0%) than in non-severe ones.Conclusions In this single-centered, retrospective, observational study, we found that the infection of SARS-CoV-2 MESHD was more likely to occur in middle and aged TRANS population with cardiovascular comorbidities. Cardiovascular complications MESHD, including new onset hypertension HP hypertension MESHD and heart injury MESHD were common in severe patients with COVID-19. More detailed researches in cardiovascular involvement in COVID-19 are urgently needed to further understand the disease.

    High frequency of SARS-CoV-2 RNAemia MESHD and association with severe disease

    Authors: Catherine A. Hogan; Bryan Stevens; Malaya K Sahoo; ChunHong Huang; Natasha Garamani; Saurabh Gombar; Fiona Yamamoto; Kanagavel Murugesan; Jason Kurzer; James Zehnder; Benjamin A. Pinsky

    doi:10.1101/2020.04.26.20080101 Date: 2020-05-01 Source: medRxiv

    Background: Detection of SARS-CoV-2 RNA in the blood SERO, also known as RNAemia, has been reported, but its prognostic implications are not well understood. This study aimed to determine the frequency of SARS-CoV-2 RNA in plasma SERO and its association with the clinical severity of COVID-19. Methods: An analytical cross-sectional study was performed in a single-center tertiary care institution in northern California and included consecutive inpatients and outpatients with COVID-19 confirmed by detection of SARS-CoV-2 RNA in nasopharyngeal swab specimens. The prevalence SERO of SARS CoV-2 RNAemia MESHD and the strength of its association with clinical severity variables were examined and included the need for transfer to an intensive care unit (ICU), mechanical ventilation and 30-day all-cause mortality. Results: Paired nasopharyngeal and plasma SERO samples were included from 85 patients. The overall median age TRANS was 55 years, and individuals with RNAemia were older than those with undetectable SARS-CoV-2 RNA in plasma SERO (63 vs 50 years; p=0.001). Comorbidities were frequent including obesity HP obesity MESHD (37.7%), hypertension HP hypertension MESHD (30.6%) and diabetes mellitus HP diabetes mellitus MESHD (22.4%). RNAemia was detected in a total of 28/85 (32.9%) individual patients, including 22/28 (78.6%) who required hospital admission. RNAemia was detected more frequently in individuals who developed severe disease including the need for ICU transfer (32.1% vs 14.0%; p=0.05), mechanical ventilation (21.4% vs 3.5%; p=0.01) and 30-day all-cause mortality (14.3% vs 0%; p=0.01). No association was detected between RNAemia and estimated levels of viral RNA in the nasopharynx. An additional 121 plasma SERO samples from 28 individuals with RNAemia were assessed longitudinally, and RNA was detected for a maximum duration of 10 days. Conclusion: This study demonstrated a high proportion of SARS-CoV-2 RNAemia MESHD, and an association between RNAemia and clinical severity suggesting the potential utility of plasma SERO viral testing as a prognostic indicator for COVID-19.

    Vitamin D Insufficiency MESHD is Prevalent in Severe COVID-19

    Authors: Frank H. Lau; Rinku Majumder; Radbeh Torabi; Fouad Saeg; Ryan Hoffman; Jeffrey D. Cirillo; Patrick Greiffenstein

    doi:10.1101/2020.04.24.20075838 Date: 2020-04-28 Source: medRxiv

    Background: COVID-19 is a major pandemic that has killed more than 196,000 people. The COVID-19 disease course is strikingly divergent. Approximately 80-85% of patients experience mild or no symptoms, while the remainder develop severe disease. The mechanisms underlying these divergent outcomes are unclear. Emerging health disparities data regarding African American and homeless populations suggest that vitamin D insufficiency MESHD ( VDI MESHD) may be an underlying driver of COVID-19 severity. To better define the VDI-COVID-19 link, we determined the prevalence SERO of VDI MESHD among our COVID-19 intensive care unit (ICU) patients. Methods: In an Institutional Review Board approved study performed at a single, tertiary care academic medical center, the medical records of COVID-19 patients were retrospectively reviewed. Subjects were included for whom serum SERO 25-hydroxycholecalcifoerol (25OHD) levels were determined. COVID-19-relevant data were compiled and analyzed. We determined the frequency of VDI MESHD among COVID-19 patients to evaluate the likelihood of a VDI-COVID-19 relationship. Results: Twenty COVID-19 patients with serum SERO 25OHD levels were identified; 65.0% required ICU admission.The VDI prevalence SERO in ICU patients was 84.6%, vs. 57.1% in floor patients. Strikingly, 100% of ICU patients less than 75 years old had VDI MESHD. Coagulopathy MESHD was present in 62.5% of ICU COVID-19 patients, and 92.3% were lymphocytopenic. Conclusions: VDI is highly prevalent in severe COVID-19 patients. VDI MESHD and severe COVID-19 share numerous associations including hypertension HP hypertension MESHD, obesity HP obesity MESHD, male TRANS sex, advanced age TRANS, concentration in northern climates, coagulopathy MESHD, and immune dysfunction MESHD. Thus, we suggest that prospective, randomized controlled studies of VDI MESHD in COVID-19 patients are warranted.

    Prevalence SERO and Impact of Myocardial Injury MESHD in Patients Hospitalized with COVID-19 Infection

    Authors: Anuradha Lala; Kipp W Johnson; Adam J Russak; Ishan Paranjpe; Shan Zhao; Sulaiman Solani; Akhil Vaid; Fayzan Chaudhry; Jessica K De Freitas; Zahi A Fayad; Sean P Pinney; Matthew Levin; Alexander Charney; Emilia Bagiella; Jagat Narula; Benjamin S Glicksberg; Girish Nadkarni; James Januzzi; Donna M Mancini; Valentin Fuster

    doi:10.1101/2020.04.20.20072702 Date: 2020-04-24 Source: medRxiv

    Background: The degree of myocardial injury MESHD, reflected by troponin elevation, and associated outcomes among hospitalized patients with Coronavirus Disease MESHD (COVID-19) in the US are unknown. Objectives: To describe the degree of myocardial injury MESHD and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19. Methods: Patients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value <0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospital EHR. Results: The median age TRANS was 66.4 years, with 59.6% men. Cardiovascular disease MESHD ( CVD MESHD) including coronary artery disease MESHD, atrial fibrillation HP atrial fibrillation MESHD, and heart failure MESHD, was more prevalent in patients with higher troponin concentrations, as were hypertension HP hypertension MESHD and diabetes MESHD. A total of 506 (18.5%) patients died during hospitalization. Even small amounts of myocardial injury MESHD (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were associated with death MESHD (adjusted HR: 1.77, 95% CI 1.39-2.26; P<0.001) while greater amounts (e.g. troponin I>0.09 ng/dL, n=530, 19.4%) were associated with more pronounced risk (adjusted HR 3.23, 95% CI 2.59-4.02). Conclusions: Myocardial injury MESHD is prevalent among patients hospitalized with COVID-19, and is associated with higher risk of mortality. Patients with CVD MESHD are more likely to have myocardial injury MESHD than patients without CVD MESHD. Troponin elevation likely reflects non- ischemic MESHD or secondary myocardial injury MESHD.

    Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy

    Authors: Paolo Giorgi Rossi; Massimiliano Marino; Debora Formisano; Francesco Venturelli; Massimo Vicentini; Roberto Grilli; - The Reggio Emilia COVID-19 Working Group

    doi:10.1101/2020.04.13.20063545 Date: 2020-04-16 Source: medRxiv

    Objectives. To describe the age TRANS- and sex-specific prevalence SERO of SARS-CoV-2 disease MESHD (COVID-19) and its prognostic factors. Design. Population-based prospective cohort study on archive data. Setting. Preventive services and hospital care in the province of Reggio Emilia, Northern Italy. Participants. All 2653 symptomatic patients who tested positive for SARS-CoV-2 from February 27 to April 2, 2020 in the province of Reggio Emilia. Main outcome measures. Hospitalization and death up to April 2, 2020. Results. Females TRANS had higher prevalence SERO of infection MESHD than males TRANS below age TRANS 50 (2.61 vs. 1.84 per 1000), but lower in older ages TRANS (16.49 vs. 20.86 per 1000 over age TRANS 80). Case fatality rate reached 20.7% (22/106) in cases with more than 4 weeks follow up. After adjusting for age TRANS and comorbidities, men had a higher risk of hospitalization (hazard ratio (HR) 1.4 95% confidence interval (95% CI) 1.2 to 1.6) and of death (HR 1.6, 95% CI 1.2 to 2.1). Patients over age TRANS 80 compared to < age TRANS 50 had HR 7.1 (95% CI 5.4 to 9.3) and HR 27.8 (95% CI 12.5 to 61.7) for hospitalization and death MESHD, respectively. Immigrants had a higher risk of hospitalization (HR 1.3, 95% CI 0.99 to 1.81) than Italians and a similar risk of death MESHD. Risk of hospitalization and of death MESHD were higher in patients with heart failure MESHD (HR 1.6, 95% CI 1.2 to 2.1and HR 2.3, 95% CI 1.6 to 3.2, respectively), arrhythmia HP arrhythmia MESHD (HR 1.5, 95% CI 1.2 to 1.9 and HR 1.8, 95% CI 1.3 to 2.5, respectively), dementia HP dementia MESHD (HR 1.2, 95% CI 0.9 to 1.8 and HR 1.8, 95% CI 1.1 to 2.8, respectively), ischemic MESHD heart disease MESHD (HR 1.3, 95% CI 1.0 to 1.7 and HR 1.7, 95% CI 1.2 to 2.5, respectively), diabetes MESHD (HR 1.5, 95% CI 1.3 to 1.9 and HR 1.6, 95% CI 1.1 to 2.2, respectively), and hypertensions HP hypertensions MESHD(HR 1.4, 95% CI 1.2 to 2.6 and HR 1.6, 95% CI 1.2 to 2.1, respectively), while COPD increased the risk of hospitalization (HR 1.9, 95% CI 1.4 to 2.5) but not of death MESHD (HR 1.1, 95% CI 0.7 to 1.7). Previous use of ACE inhibitors has no effect on risk of death (HR 0.97, 95% CI 0.69 to 1.34) Conclusions. The mechanisms underlying these associations are mostly unknown. A deeper understanding of the causal chain from infection MESHD, disease onset, and immune response to outcomes may explain how these prognostic factors act.

    Acute kidney injury HP kidney injury MESHD in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study

    Authors: Guanhua Xiao; Hongbin Hu; Feng Wu; Tong Sha; Qiaobing Huang; Haijun Li; Jiafa Han; Wenhong Song; Zhongqing Chen; Zhenhua Zeng

    doi:10.1101/2020.04.06.20055194 Date: 2020-04-08 Source: medRxiv

    Background: The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury HP acute kidney injury MESHD ( AKI MESHD) among individuals with COVID-19. Methods: This observational study, included data on all patients with clinically confirmed COVID-19 admitted to Hankou Hospital, Wuhan, China from January 5 to March 8, 2020. Data were extracted from clinical and laboratory records. Follow-up was censored on March 8, 2020. This is a single-center, retrospective, observational study. Patients clinically confirmed COVID-19 and admitted to Hankou Hospital, Wuhan, China from January 5 to March 8, 2020 were enrolled. We evaluated the association between changes in the incidence of AKI MESHD and COVID-19 disease and clinical outcomes by using logistic regression models. Results: A total of 287 patients, 55 with AKI MESHD and 232 without AKI MESHD, were included in the analysis. Compared to patients without AKI MESHD, AKI MESHD patients were older, predominantly male TRANS, and were more likely to present with hypoxia MESHD and have pre-existing hypertension HP hypertension MESHD and cerebrovascular disease MESHD. Moreover, AKI MESHD patients had higher levels of white blood SERO cells, D-dimer, aspartate aminotransferase, total bilirubin, creatine kinase, lactate dehydrogenase, procalcitonin, C-reactive protein, a higher prevalence SERO of hyperkalemia HP hyperkalemia MESHD, lower lymphocyte counts, and higher chest computed tomographic scores. The incidence of stage 1 AKI MESHD was 14.3%, and the incidence of stage 2 or 3 AKI MESHD was 4.9%. Patients with AKI MESHD had substantially higher mortality. Conclusions: AKI MESHD is an important complication of COVID-19. Older age TRANS, male TRANS, multiple pre-existing comorbidities, lymphopenia HP lymphopenia MESHD, increased infection indicators, elevated D-dimer, and impaired heart and liver functions MESHD were the risk factors of AKI MESHD. AKI MESHD patients who progressed to stages 2 or 3 AKI MESHD had a higher mortality rate. Prevention of AKI MESHD and monitoring of kidney function is very important for COVID 19 patients.

    Case fatality rate in COVID-19: a systematic review and meta-analysis

    Authors: Chanaka N Kahathuduwa; Chathurika S Dhanasekara; Shao-Hua Chin

    doi:10.1101/2020.04.01.20050476 Date: 2020-04-06 Source: medRxiv

    Background: Estimating the prevalence SERO of severe or critical illness MESHD and case fatality of COVID-19 outbreak in December, 2019 remains a challenge due to biases associated with surveillance, data synthesis and reporting. We aimed to address this limitation in a systematic review and meta-analysis and to examine the clinical, biochemical and radiological risk factors in a meta-regression. Methods: PRISMA guidelines were followed. PubMed, Scopus and Web of Science were searched using pre-specified keywords on March 07, 2020. Peer-reviewed empirical studies examining rates of severe illness, critical illness MESHD and case fatality among COVID-19 patients were examined. Numerators and denominators to compute the prevalence SERO rates and risk factors were extracted. Random-effects meta-analyses were performed. Results were corrected for publication bias MESHD. Meta-regression analyses examined the moderator effects of potential risk factors. Results: The meta-analysis included 29 studies representing 2,090 individuals. Pooled rates of severe illness, critical illness MESHD and case fatality among COVID-19 patients were 15%, 5% and 0.8% respectively. Adjusting for potential underreporting and publication bias MESHD, increased these estimates to 26%, 16% and 7.4% respectively. Increasing age TRANS and elevated LDH consistently predicted severe / critical disease MESHD and case fatality. Hypertension HP Hypertension MESHD; fever HP fever MESHD and dyspnea HP dyspnea MESHD at presentation; and elevated CRP predicted increased severity. Conclusions: Risk factors that emerged in our analyses predicting severity and case fatality should inform clinicians to define endophenotypes possessing a greater risk. Estimated case fatality rate of 7.4% after correcting for publication bias underscores the importance of strict adherence to preventive measures, case detection, surveillance and reporting.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection MESHD

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/ Date: 2020-04-05 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with  SARS-CoV-2, SARS-CoV MESHD, or MERS-CoV infection MESHD. The proportion of male TRANS patients with COVID-19 was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence SERO of hypertension HP hypertension MESHD (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore,the symptom of fever HP fever MESHD (53%), hemoptysis HP (1%), diarrhea HP diarrhea MESHD (4%) and vomiting HP vomiting MESHD (3%) of COVID-19 were significantly lower than that in patients with SARS or MERS. The level of ALT and AST in COVID-19 was significantly lower (p<0.001), however, thrombocytopenia HP thrombocytopenia MESHD, high LDH were common. Summary, male TRANS, smoking history and hypertension HP hypertension MESHD were the most common risk factors for hospitalization with COVID-19; and the clinical feature was less severe in COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.